Recruiting
To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
NCT07280494
- Conditions
- CD7+ T-ALL/LBL, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
- Locations
-
- Peking University People's Hospital Beijing, China